Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Article
CAS
PubMed
Google Scholar
Jemal A, Bray F, Center MM, et al. Global Cancer statistics. CA Cancer J Clin [Internet]. 2011;61:69–90.
Article
Google Scholar
Kawano Y, Sasaki A, Kai S, et al. Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol. 2008;15:1670–6.
Article
PubMed
Google Scholar
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schrohl AS, Holten-Andersen M, Sweep F, et al. Tumor Markers. Mol Cell Proteomics. 2003;2:378–87.
Article
CAS
PubMed
Google Scholar
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.
Article
PubMed
Google Scholar
Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
Article
Google Scholar
Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015;45:123–7.
Article
Google Scholar
Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol. 2005;19:91–9.
Article
CAS
PubMed
Google Scholar
Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20:563–9.
Article
CAS
PubMed
Google Scholar
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.
Article
CAS
PubMed
Google Scholar
Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptor. Science. 2004;306:1506–7.
Article
CAS
PubMed
Google Scholar
Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t (4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90:4062–70.
Article
CAS
PubMed
Google Scholar
Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of 11qI3 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003;201:603–8.
Article
CAS
PubMed
Google Scholar
Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t (8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84–7.
Article
CAS
PubMed
Google Scholar
Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res. 2003;63:6116–20.
CAS
PubMed
Google Scholar
Ruohola JK, Viitanen TP, Valve EM, et al. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 2001;61:4229–37.
CAS
PubMed
Google Scholar
Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005;92:320–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21 : from feast to famine. Genes Dev. 2012;26:312–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:139–44.
Article
CAS
PubMed
Google Scholar
Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hyeon J, Ahn S, Lee JJ, et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci. 2013;58:1916–22.
Article
CAS
PubMed
Google Scholar
Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation Am Fam Physician. 2006;74:756–62.
PubMed
Google Scholar
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
Article
PubMed
Google Scholar
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
Article
PubMed
Google Scholar
Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:111–7.
Article
CAS
PubMed
Google Scholar
Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10.
Article
PubMed
PubMed Central
Google Scholar
Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333–51.
Article
CAS
PubMed
Google Scholar
Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011;19:347–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.
Article
CAS
PubMed
Google Scholar
Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976–85.
Article
CAS
PubMed
Google Scholar
Strutz F, Zeisberg M, Hemmerlein B, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 2000;57:1521–38.
Article
CAS
PubMed
Google Scholar
Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410–33.
Article
CAS
PubMed
Google Scholar
Toyoda H, Kumada T, Tada T, et al. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4:126–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18:71–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ashby K, Navarro Almario EE, Tong W, et al. Review article: therapeutic bile acids and the risks for hepatotoxicity. Aliment Pharmacol Ther. 2018;47:1623–38.
Article
CAS
PubMed
Google Scholar
John Y. L. Chiang. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955–66.
Article
CAS
Google Scholar
Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009;49:297–305.
Article
CAS
PubMed
Google Scholar
Lin BC, Desnoyers LR. FGF19 and Cancer. Adv Exp Med Biol. 2012;728:183–94.
Article
CAS
PubMed
Google Scholar
Repana D, Ross P. Targeting FGF19/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma. Diseases. 2015;3:294–305.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zheng N, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res. 2016;5:1–6.
Article
PubMed
CAS
Google Scholar
Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052–74.
PubMed
Google Scholar
Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gao L, Wang X, Tang Y, et al. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017;36:8.
Article
PubMed
PubMed Central
CAS
Google Scholar